Equities research analysts predict that Encompass Health Corp (NYSE:EHC) will post $1.06 billion in sales for the current quarter, according to Zacks. Six analysts have made estimates for Encompass Health’s earnings, with estimates ranging from $1.05 billion to $1.07 billion. Encompass Health posted sales of $995.60 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 6.5%. The business is expected to issue its next earnings results on Thursday, October 25th.
According to Zacks, analysts expect that Encompass Health will report full-year sales of $4.26 billion for the current financial year, with estimates ranging from $4.24 billion to $4.28 billion. For the next fiscal year, analysts expect that the business will post sales of $4.51 billion per share, with estimates ranging from $4.47 billion to $4.54 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Encompass Health.
Encompass Health (NYSE:EHC) last released its quarterly earnings data on Wednesday, July 25th. The company reported $0.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.16. Encompass Health had a net margin of 7.32% and a return on equity of 22.57%. The company had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.03 billion.
Several equities research analysts have recently issued reports on EHC shares. Mizuho reissued a “buy” rating and issued a $82.00 price objective on shares of Encompass Health in a research report on Thursday, July 26th. Credit Suisse Group raised their price target on shares of Encompass Health from $66.00 to $80.00 and gave the company an “outperform” rating in a report on Thursday, July 26th. Finally, Piper Jaffray Companies raised shares of Encompass Health from a “neutral” rating to an “overweight” rating in a report on Thursday, July 26th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $73.00.
Shares of Encompass Health stock traded up $0.37 during trading hours on Friday, hitting $80.52. The company’s stock had a trading volume of 390,300 shares, compared to its average volume of 682,521. Encompass Health has a 1-year low of $43.32 and a 1-year high of $82.46. The firm has a market capitalization of $7.90 billion, a P/E ratio of 29.09, a PEG ratio of 1.89 and a beta of 0.31. The company has a quick ratio of 1.17, a current ratio of 1.17 and a debt-to-equity ratio of 1.73.
The company also recently declared a quarterly dividend, which will be paid on Monday, October 15th. Investors of record on Monday, October 1st will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 1.34%. This is a positive change from Encompass Health’s previous quarterly dividend of $0.25. The ex-dividend date is Friday, September 28th. Encompass Health’s dividend payout ratio (DPR) is presently 36.23%.
About Encompass Health
Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates through two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.
Recommended Story: How is a Moving Average Calculated?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.